OTCM
GBLX
Market cap40kUSD
Oct 08, Last price
0.00USD
1D
0.00%
1Q
-66.67%
Jan 2017
-99.97%
IPO
-99.91%
Name
GB Sciences Inc
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
13.62%
Rev. gr., 5y
7.52%
Revenues
0
Net income
-1m
L-66.98%
CFO
-976k
L-36.10%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Operating across North America and Europe, GB Sciences, Inc. is dedicated to the research and development of plant-based pharmaceuticals. The company specializes in crafting cannabinoid-inspired medications and complex therapeutic formulations intended for the prescription drug market. Its extensive intellectual property portfolio addresses a variety of medical conditions, with programs currently in pre-clinical animal stages. These include initiatives for Parkinson's disease, neuropathic and chronic pain, COVID-related cytokine release syndrome, depression/anxiety, and cardiovascular ailments. Formed in 2001 and headquartered in Las Vegas, Nevada, the company was formerly known as Growblox Sciences, Inc. before rebranding in October 2016.
Key people
Zach Swarts
Interim Chief Financial Officer · since 2019
Krin Ellery Kuethe
Senior Vice President - Cultivation · since 2018
Darin Carpenter
Executive Vice President - Operations, General Manager · since 2019
Edmond DeFrank
Director · since 2019
John Poss
Chairman of the Board, President, Chief Executive Officer · since 2017
Andrea Small-Howard
Chief Science Officer, Director · since 2014
Leslie Bocskor
Independent Vice Chairman of the Board · since 2017
Legal address
C/O A Registered Agent Inc.
8 The Green
Suite A
Dover, DE 19901
US
8 The Green
Suite A
Dover, DE 19901
US
Headquarters
4700 Millenia Boulevard
Suite 175
Orlando, FL 32829
US
Suite 175
Orlando, FL 32829
US
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|
| 2024‑03 | 2023‑03 | 2022‑03 | 2021‑03 | 2020‑03 | 2019‑03 | 2018‑03 | 2017‑03 | |
| Income | ||||||||
Revenues | ||||||||
Cost of revenue | ||||||||
Unusual Expense (Income) | ||||||||
NOPBT | ||||||||
NOPBT Margin | ||||||||
Operating Taxes | ||||||||
Tax Rate | ||||||||
NOPAT | ||||||||
Net income | ||||||||
Dividends | ||||||||
Dividend yield | ||||||||
Proceeds from repurchase of equity | ||||||||
BB yield | ||||||||
| Debt | ||||||||
Debt current | ||||||||
Long-term debt | ||||||||
Deferred revenue | ||||||||
Other long-term liabilities | ||||||||
Net debt | ||||||||
| Cash flow | ||||||||
Cash from operating activities | ||||||||
CAPEX | ||||||||
Cash from investing activities | ||||||||
Cash from financing activities | ||||||||
FCF | ||||||||
| Balance | ||||||||
Cash | ||||||||
Long term investments | ||||||||
Excess cash | ||||||||
Stockholders' equity | ||||||||
Invested Capital | ||||||||
ROIC | ||||||||
ROCE | ||||||||
| EV | ||||||||
Common stock shares outstanding | ||||||||
Price | ||||||||
Market cap | ||||||||
EV | ||||||||
EBITDA | ||||||||
EV/EBITDA | ||||||||
Interest | ||||||||
Interest/NOPBT | ||||||||